Nykredit A S Acquires New Holdings in Medline $MDLN

Key Points

• Nykredit A/S acquired 36,116 Medline shares during the second quarter, valued at approximately $1.42 million. Several other institutional investors also initiated or increased positions.
• Analysts maintain a generally positive outlook, with Medline receiving a consensus “Moderate Buy” rating and an average price target of $47.42, despite some recent target-price reductions.
• Medline’s shares opened at $36.59, while insiders sold 4.54 million shares worth approximately $161.9 million in the last quarter. The company recently exceeded earnings expectations, reporting quarterly EPS of $0.50 versus the $0.32 consensus estimate.

Nykredit A S purchased a new stake in Medline (NASDAQ:MDLN - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 36,116 shares of the company's stock, valued at approximately $1,424,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Entrust Financial LLC bought a new position in Medline during the 4th quarter worth approximately $26,000. GAMMA Investing LLC increased its position in shares of Medline by 68.3% during the second quarter. GAMMA Investing LLC now owns 626 shares of the company's stock worth $25,000 after buying an additional 254 shares during the period. Whipplewood Advisors LLC bought a new position in Medline during the first quarter worth $30,000. Global Retirement Partners LLC acquired a new position in Medline in the fourth quarter valued at $31,000. Finally, Whittier Trust Co. bought a new stake in Medline during the first quarter valued at $49,000.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on MDLN. BTIG Research reissued a "buy" rating and issued a $55.00 price objective on shares of Medline in a research report on Thursday, August 27th. Deutsche Bank Aktiengesellschaft set a $37.00 target price on Medline in a report on Thursday, August 6th. Weiss Ratings raised Medline from a "sell (d)" rating to a "sell (d+)" rating in a research note on Thursday, August 6th. Barclays cut their price target on Medline from $50.00 to $45.00 and set an "overweight" rating on the stock in a report on Monday, June 1st. Finally, Truist Financial reduced their price objective on shares of Medline from $56.00 to $47.00 and set a "buy" rating for the company in a research report on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $47.42.

Insider Activity

In related news, insider Douglas Golwas sold 100,000 shares of the firm's stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $36.77, for a total transaction of $3,677,000.00. Following the transaction, the insider directly owned 23,899 shares of the company's stock, valued at $878,766.23. This trade represents a 80.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Private Ltd Gic sold 100,000 shares of the business's stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $35.80, for a total transaction of $3,580,000.00. Following the transaction, the insider owned 22,802,482 shares in the company, valued at approximately $816,328,855.60. This trade represents a 0.44% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 4,538,896 shares of company stock valued at $161,936,454. 0.81% of the stock is currently owned by corporate insiders.

Medline Price Performance

Shares of MDLN opened at $36.59 on Tuesday. Medline has a 12-month low of $32.49 and a 12-month high of $50.88. The business's fifty day moving average is $37.81 and its 200 day moving average is $40.21. The company has a quick ratio of 2.61, a current ratio of 4.33 and a debt-to-equity ratio of 0.66. The stock has a market cap of $48.11 billion and a P/E ratio of 46.32.

Medline (NASDAQ:MDLN - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.32 by $0.18. The business had revenue of $7.68 billion for the quarter. Sell-side analysts anticipate that Medline will post 1.51 earnings per share for the current fiscal year.

Medline Company Profile

Medline NASDAQ: MDLN is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.